Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

被引：18

作者：

Powles, Thomas

Choueiri, Toni K.

Burotto, Mauricio

Escudier, Bernard

Bourlon, Maria Teresa

Shah, Amishi Yogesh

Suarez, Cristina

Hamzaj, Alketa

Porta, Camillo

Hocking, Christopher

Kessler, Elizabeth R.

Gurney, Howard

Tomita, Yoshihiko

Bedke, Jens

Zhang, Joshua

Simsek, Burcin

Scheffold, Christian

Apolo, Andrea B.

Motzer, Robert J.

机构：

[1] Queen Mary Univ London, Canc Res UK Expt Canc Med Ctr, Barts Canc Inst, London, England

[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA

[3] Harvard Med Sch, Boston, MA 02115 USA

[4] Bradford Hill Clin Res Ctr, Santiago, Chile

[5] Gustave Roussy, Villejuif, France

[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Vall dHebron Barcelona Hosp Campus, Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[9] Ist Toscano Tumori, Osped San Donato, Arezzo, Italy

[10] Univ Pavia, Pavia, Italy

[11] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia

[12] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA

[13] Westmead Hosp, Sydney, NSW, Australia

[14] Macquarie Univ Hosp, Sydney, NSW, Australia

[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[16] Eberhand Karls Univ Tubingen, Tubingen, Germany

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Exelixis Inc, Alameda, CA USA

[19] NCI, NIH, Bethesda, MD 20892 USA

[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.350

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

350

引用

页数：4

共 47 条

[1] Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
Tarigopula, Vivek
INDIAN JOURNAL OF UROLOGY, 2022, 38 (04) : 317 - 318
[2] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
Powles, T.
Burotto, M.
Escudier, B.
Apolo, A. B.
Bourlon, M. T.
Shah, A. Y.
Suarez, C.
Porta, C.
Barrios, C. H.
Richardet, M.
Gurney, H.
Kessler, E. R.
Tomita, Y.
Bedke, J.
George, S.
Scheffold, C.
Wang, P.
Fedorov, V.
Motzer, R. J.
Choueiri, T. K.
ESMO OPEN, 2024, 9 (05)
[3] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[4] Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Benjamin Duy Tran
Jing Li
Neang Ly
Raffaella Faggioni
Lorin Roskos
Cancer Chemotherapy and Pharmacology, 2023, 91 : 179 - 189
[5] Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Tran, Benjamin Duy
Li, Jing
Ly, Neang
Faggioni, Raffaella
Roskos, Lorin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 179 - 189
[6] Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)
Mantia, Charlene
Jegede, Opeyemi
Viray, Hollis
Atkins, Michael B.
Rosenblatt, Lisa
Yin, Xin
McDermott, David F.
Regan, Meredith M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Motzer, Robert J.
Powles, Thomas
Burotto, Mauricio
Apolo, Andrea B.
Escudier, Bernard
McDermott, David F.
Braun, David A.
Han, Celine
Lee, George
Dwivedi, Bhakti
Li, Jun
Gupta, Saurabh
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[9] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
Bourlon, Maria Teresa
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Wang, Fong
Wang, Peter
Panzica, Julie
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 362 - 362
[10] Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
Cella, David
Choueiri, Toni K.
Blum, Steven, I
Ejzykowicz, Flavia
Hamilton, Melissa
Zhang, Joshua
Ivanescu, Cristina
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →